Medtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System
Portfolio Pulse from
Medtronic announced that the Centers for Medicare & Medicaid Services (CMS) is conducting a national coverage analysis for the Symplicity™ Spyral Renal Denervation System, a minimally invasive treatment for high blood pressure. This analysis could lead to a national Medicare coverage policy, driven by significant public health needs and strong clinical data.
January 13, 2025 | 9:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medtronic's Symplicity™ Spyral Renal Denervation System is under CMS national coverage analysis, which could lead to Medicare coverage for this hypertension treatment. This is a significant regulatory milestone supported by robust clinical data.
The CMS national coverage analysis is a critical step towards Medicare coverage for Medtronic's Symplicity™ Spyral RDN System. This could significantly increase the system's market reach and adoption, positively impacting Medtronic's revenues and stock price. The analysis is backed by strong clinical data, enhancing the likelihood of a favorable outcome.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100